Estrasorb NDA withdrawn
Executive Summary
Novavax expects to resubmit NDA for estrogen replacement cream Estrasorb within 90 days following voluntary withdrawal due to chemistry, manufacturing and controls issues. Resubmission will include an assay validation on content uniformity and another degradation study...
You may also be interested in...
Novavax Estrasorb review extension
FDA extends Novavax Estrasorb July 12 user fee date by three months to Oct. 10. Company expects extension of review period will not delay its planned launch for the first quarter of 2004. Novavax voluntarily withdrew the estrogen replacement cream NDA in April 2002 due to chemistry, manufacturing and controls concerns (1"The Pink Sheet" April 29, 2002, In Brief)...
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.